Makers say Tysabri extends remissions in Crohn's disease

10/24/2006 |

The Tysabri drug approved for treating multiple sclerosis has been shown in clinical trials to maintain Crohn's disease remissions in patients treated for more than two years. Biogen Idec and Elan Corp., co-producers of Tysabri, reported tests using Tysabri on patients previously given Johnson & Johnson's Remicade resulted in 91% of patients still in remission after infusions.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care